Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Telegram Restored on Apple App Store After Temporary Removal 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SOUTH SAN FRANCISCO, Calif., April 03, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco on Tuesday, April 10 at 9:00 a.m. Central European Time.
The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section.
About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
